Prosecution Insights
Last updated: October 25, 2026
Application No. 17/995,356

FLUORESCENT DYES HAVING HIGH STOKES SHIFT, ON THE BASIS OF BRIDGED BENZOPYRYLIUM SALTS

Final Rejection §102§103
Filed
Oct 03, 2022
Priority
Apr 03, 2020 — DE 10 2020 109 362.4 +1 more
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dyomics GmbH
OA Round
4 (Final)
46%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
418 granted / 906 resolved
-13.9% vs TC avg
Strong +22% interview lift
Without
With
+22.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
47 currently pending
Career history
965
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
22.2%
-17.8% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 906 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Amendments Applicants amendments to the claims filed 7/9/2026 have been entered. Any objection\rejections from the previous office action filed 5/12/2026 not addressed below has been withdrawn. Election/Restrictions By amendment the examiners elected species no longer reads on the amended claims. Therefore the search has been extended to a compound of formula I in which R3 is NR18R19, where R18 is hydrogen and R19 is substituted aryl, R11 and R12 are methyl and all other R groups are H. If prior art is then found that anticipates or renders obvious the Markush-type claim with respect to a nonelected species, the Markush-type claim shall be rejected and claims to the nonelected species held withdrawn from further consideration. The prior art search, however, will not be extended unnecessarily to cover all nonelected species. Should applicant, in response to this rejection of the Markush-type claim, overcome the rejection, as by amending the Markush-type claim to exclude the species anticipated or rendered obvious by the prior art, the amended Markush-type claim will be reexamined. The ** > examination < will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during the reexamination that anticipates or renders obvious the amended Markush-type claim, the claim will be rejected and the action can be made final unless the examiner introduces a new ground of rejection that is neither necessitated by applicant' s amendment of the claims nor based on information submitted in an information disclosure statement filed during the period set forth in 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p). See MPEP § 706.07(a). Amendments submitted after the final rejection further restricting the scope of the claim may be denied entry if they do not comply with the requirements of 37 CFR 1.116. See MPEP § 714.13.See MPEP 803.02. Claims 2,4,6,11-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention or species, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1,3,5,7 and 9 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Olekhnovich et al. “Acetals and Vinyl Ethers of Unsaturated Aldehydes and Ketones in the New Syntheses of Heterocyclic Compounds: XII.* New Alternatives of Acid Condensation of Cyclohexane-1,4-diones with Hydroxyarylaldehydes under Dehydration Conditions. Fluorecence Spectra of the Products**”, Russian Journal of Organic Chemistry, Vol. 37, No. 4, 2001, pp. 5273538, cited by applicants. Olekhnovich discloses compounds of the following formula: PNG media_image1.png 466 820 media_image1.png Greyscale , IX reads on the elected compound when R1 is H, R2 is 4-HOOCC6H4 and R3 is H. See entire disclosure, especially scheme 2. Note XIIa is in equilibrium with VII, it follows that some XIIa would react with R2R3N to produce an IX where R1 is H. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1,3,5,7 and 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Olekhnovich et al., cited above. While the examiner believes Olekhnovich anticipates the claimed invention, it also follows that replacing the methoxy group for H in R1 for the compounds encompassed by IX above would be obvious. Obviousness stems from the fact that Olekhnovich already teaches compound VIIa in which R1 is H. One of ordinary skill could reason that compound XIIa could also react with the reactive amine R2R3NH2 to form compound IX where R1 is H. Since the compounds are very close structurally one of ordinary skill would have a high expectation of success in making such a modification. An obviousness rejection based on similarity in chemical structure and function entails the reason for one of ordinary skill in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties. Response to Arguments Applicant's arguments filed 5/12/2026 have been fully considered but they are not persuasive. Applicants assert that the amendments have overcome the prior art rejections. For the reasons above the examiner believes Olekhnovich still anticipates and/or renders obvious the claimed invention. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/ Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Show 2 earlier events
Nov 24, 2025
Response Filed
Jan 09, 2026
Final Rejection mailed — §102, §103
Mar 04, 2026
Response after Non-Final Action
Apr 06, 2026
Request for Continued Examination
Apr 07, 2026
Response after Non-Final Action
May 12, 2026
Non-Final Rejection mailed — §102, §103
Jul 09, 2026
Response Filed
Sep 14, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12759047
Metal-based core nanoparticles, synthesis and use
4y 3m to grant Granted Oct 13, 2026
Patent 12758636
POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS
3y 6m to grant Granted Oct 13, 2026
Patent 12758658
DOUBLE-COMPONENT GASTRIC ULTRASOUND EXAMINATION AIDED DEVELOPER AND PREPARATION METHOD THEREFOR
2y 10m to grant Granted Oct 13, 2026
Patent 12741033
NOOTROPIC FULLERENES AND USE
4y 7m to grant Granted Sep 22, 2026
Patent 12708603
NOVEL TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES BIO MODULATED CERAMICS
5y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
46%
Grant Probability
68%
With Interview (+22.4%)
3y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 906 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month